Keep a close eye on Minerva Neurosciences, Inc. (NERV). The company reported positive data that support the use of MIN-202 in the treatment of both primary insomnia as well as sleep disorders associated with major depressive disorder.
Sleep is increasingly recognized as important to public health, with sleep insufficiency linked to motor vehicle crashes, industrial disasters, and medical and other occupational errors
Insomnia, one of the most common sleep disorders, is difficulty falling asleep or staying asleep, even when a person has the chance to do so. People with insomnia can feel dissatisfied with their sleep and usually experience one or more of the following: fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance in work or at school.
The cumulative effects of sleep loss and sleep disorders represent an under-recognized public health problem and have been associated with a wide range of health consequences including an increased risk of hypertension, diabetes, obesity, depression, heart attack, and stroke.
NERV said that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features.
These preliminary results provide additional support for progression of MIN-202 into next stage of clinical development.
In patients with mood disorders, sleep disturbances (both insomnia and hypersomnia) have been associated with a suboptimal response to antidepressant drug (AD) therapy, an increased risk for relapse (in AD-responsive patients), and prodromal depression. Recent studies have shown that orexin-2 receptor antagonism might have a beneficial effect on overall arousal and stress level.
MIN-202 is an orexin-2 (OX) antagonist being developed by NERV in collaboration with Janssen Pharmaceutica NV, for the treatment of sleep disorders.
NERV is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases.
More about Minerva Neurosciences, Inc. (NERV) at www.minervaneurosciences.com
**
eBay Inc. (EBAY) reported strong performance on its financial results, driven by enabled commerce volume growth of 21%.
For the fourth quarter 2014, EBAY posted net revenue of $4.9 billion, a 9% increase year over year, and non-GAAP net income of $1.11 billion or $0.90 per diluted share, compared to non-GAAP net income of $1.07 billion or $0.81 per diluted share in the same period the prior year and better than analysts’ average estimate of $0.89 per share.
For the first quarter 2015, EBAY expects non-GAAP earnings per diluted share in the range of $0.68 - $0.71. Looking forward to 2015, EBAY plans to explore strategic options for eBay Enterprise, which advises retailers on e-commerce, including a sale or IPO.
EBAY said that it has entered into a standstill agreement with billionaire investor Carl Icahn, its largest active shareholder. As part of the agreement, EBAY has appointed Icahn Capital executive Jonathan Christodoro to its board of directors.
According to EBAY, its plans to separate the company’s eBay and PayPal businesses into two independent publicly traded companies in 2015 are on track and this is the right strategic path for each business. The agreement with Mr. Icahn allows him to determine which board Mr. Christodoro will serve on at the time of separation.
EBAY is a global commerce and payments leader, providing a robust platform where merchants of all sizes can compete and win.
More about eBay Inc. (EBAY) at www.ebayinc.com.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Salinas, CA ( www.salinas.crwe-pr.com ) into the CRWE Network.
Salinas is the county seat and largest municipality of Monterey County, California. It is located in central California about twenty minutes from the coast and twenty-five minutes northeast of Monterey. The California Rodeo, California International Airshow, and the world famous Steinbeck Festival are major attractions of Salinas. Some of the largest employers in the area include: Dole Fresh Vegetable, the County of Monterey, and Salinas Valley Memorial Hospital.
The City of Salinas had an estimated population in 2013 (U.S. Census Bureau) of 155,662, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
Sleep is increasingly recognized as important to public health, with sleep insufficiency linked to motor vehicle crashes, industrial disasters, and medical and other occupational errors
Insomnia, one of the most common sleep disorders, is difficulty falling asleep or staying asleep, even when a person has the chance to do so. People with insomnia can feel dissatisfied with their sleep and usually experience one or more of the following: fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance in work or at school.
The cumulative effects of sleep loss and sleep disorders represent an under-recognized public health problem and have been associated with a wide range of health consequences including an increased risk of hypertension, diabetes, obesity, depression, heart attack, and stroke.
NERV said that preliminary results from a Phase 1 clinical study showed that treatment with MIN-202, a selective orexin-2 antagonist, resulted in significant improvements in sleep onset and sleep duration in patients with comorbid insomnia related to major depressive disorder (MDD). Preliminary results from two additional Phase 1 studies also suggest that MIN-202 is well tolerated and possesses advantageous pharmacokinetic and pharmacodynamic features.
These preliminary results provide additional support for progression of MIN-202 into next stage of clinical development.
In patients with mood disorders, sleep disturbances (both insomnia and hypersomnia) have been associated with a suboptimal response to antidepressant drug (AD) therapy, an increased risk for relapse (in AD-responsive patients), and prodromal depression. Recent studies have shown that orexin-2 receptor antagonism might have a beneficial effect on overall arousal and stress level.
MIN-202 is an orexin-2 (OX) antagonist being developed by NERV in collaboration with Janssen Pharmaceutica NV, for the treatment of sleep disorders.
NERV is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases.
More about Minerva Neurosciences, Inc. (NERV) at www.minervaneurosciences.com
**
eBay Inc. (EBAY) reported strong performance on its financial results, driven by enabled commerce volume growth of 21%.
For the fourth quarter 2014, EBAY posted net revenue of $4.9 billion, a 9% increase year over year, and non-GAAP net income of $1.11 billion or $0.90 per diluted share, compared to non-GAAP net income of $1.07 billion or $0.81 per diluted share in the same period the prior year and better than analysts’ average estimate of $0.89 per share.
For the first quarter 2015, EBAY expects non-GAAP earnings per diluted share in the range of $0.68 - $0.71. Looking forward to 2015, EBAY plans to explore strategic options for eBay Enterprise, which advises retailers on e-commerce, including a sale or IPO.
EBAY said that it has entered into a standstill agreement with billionaire investor Carl Icahn, its largest active shareholder. As part of the agreement, EBAY has appointed Icahn Capital executive Jonathan Christodoro to its board of directors.
According to EBAY, its plans to separate the company’s eBay and PayPal businesses into two independent publicly traded companies in 2015 are on track and this is the right strategic path for each business. The agreement with Mr. Icahn allows him to determine which board Mr. Christodoro will serve on at the time of separation.
EBAY is a global commerce and payments leader, providing a robust platform where merchants of all sizes can compete and win.
More about eBay Inc. (EBAY) at www.ebayinc.com.
**
Crown Equity Holdings Inc. (CRWE) is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Salinas, CA ( www.salinas.crwe-pr.com ) into the CRWE Network.
Salinas is the county seat and largest municipality of Monterey County, California. It is located in central California about twenty minutes from the coast and twenty-five minutes northeast of Monterey. The California Rodeo, California International Airshow, and the world famous Steinbeck Festival are major attractions of Salinas. Some of the largest employers in the area include: Dole Fresh Vegetable, the County of Monterey, and Salinas Valley Memorial Hospital.
The City of Salinas had an estimated population in 2013 (U.S. Census Bureau) of 155,662, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance ( www.finance.crwe-pr.com ) is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
